Search

Search Results

• 

  The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey

  Silvia Linari, Renato Marino, Marzia Leotta, Antonio Coppola, Patrizia Di Gregorio, Augusto Bramante Federici, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro

  05-11-2025

  https://doi.org/10.4081/btvb.2025.369

  1316

  PDF: 213

  HTML: 129

  Appendix: 119
• 

  Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

  Ezio Zanon, Giancarlo Castaman, Augusto Bramante Federici, Maria Elisa Mancuso, Gianfranco Pasut, Alberto Tosetto, Angiola Rocino, Rita Carlotta Santoro

  26-01-2026

  https://doi.org/10.4081/btvb.2026.415

  1234

  PDF: 333

  HTML: 156

• PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.307

  598

  PDF: 17
• 

  Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life

  Ilaria Nichele, Giuseppe Carli, Alberto Tosetto

  22-04-2024

  https://doi.org/10.4081/btvb.2024.104

  1054

  PDF: 371
• 

  The changing landscape of treatment for acquired hemophilia A

  Massimo Franchini, Daniele Focosi

  30-01-2025

  https://doi.org/10.4081/btvb.2025.157

  2038

  PDF: 544
• 

  Growing weapons to fight hemophilia

  Pier Mannuccio Mannucci

  23-02-2023

  https://doi.org/10.4081/btvb.2023.64

  1465

  PDF: 571

• PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.318

  635

  PDF: 15

• PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti¹, S. Ligia¹, F. Paoletti¹, R. Mormile¹, E. Baldacci², A. Chistolini¹, C. Santoro^1,2 | ¹Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; ²Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.285

  597

  PDF: 15

• PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.334

  597

  PDF: 18

• PO90 | Acquired hemophilia A with high-titer inhibitor in a patient with cardiovascular and metabolic comorbidities M.G. Mazzone, G. Chiarelli, R. Russo, L. Valletta Jr, G. D’Errico, C. De Luca, P. Rufolo, A. Tufano, E. Cimino, P. Conca, M.N.D. Di Minno | Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.360

  639

  PDF: 15

• PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.355

  729

  PDF: 17